Amplia Therapeutics (ASX:ATX) has announced updated data from its ongoing ACCENT clinical trial of its narmafotinib in combination with chemotherapies gemcitabine and abraxane in pancreatic cancer.
Narmafotinib is an inhibitor of the FAK, a protein over-expressed in pancreatic cancer and a drug target gaining increasing attention for its role in solid tumours.
Amplia said 15 confirmed partial responses have now been recorded in the trial. It said this level of response is sufficient to demonstrate that the combination of narmafotinib and chemotherapy is superior to chemotherapy alone. A confirmed partial response is a formal designation where tumour shrinkage of greater than 30 per cent is recorded and sustained for two or more months and where no new cancerous lesions have been detected.
A total of 55 advanced pancreatic patients have enrolled in the study since January 2024, with 21 patients still on study.
Amplia CEO and managing director Dr Chris Burns said, “We are extremely excited to have now recorded 15 confirmed partial responses in the ACCENT trial, demonstrating the benefit of adding narmafotinib to standard-of-care chemotherapy. With over 20 patients still on study we are hopeful that further PR’s will be observed,”